Early Phase Patient Studies
PRA Early Development Services conduct clinical trials in both healthy volunteers and patient populations and are committed to the highest standards of clinical excellence and scientific expertise.
Because of an increased interest in having patient safety and efficacy data available as early as possible during the clinical pharmacology program PRA has invested substantially within this area to support our client’s needs.
Each of our eight clinical pharmacology centers has the capabilities and experience to quickly randomize patients, and four of our centers are 100% dedicated to early phase patient studies, both in Europe and the USA.
Within Central and Eastern Europe, PRA has established an innovative Patient Pharmacology Services (PPS) group dedicated to early phase patient studies. PPS performs early patient trials in collaboration with an extensive network of investigators in Central Eastern European countries such as Hungary, Poland, Czech Republic, and Slovakia. Centralized health-care systems with a limited number of hospitals focusing on certain diseases are characterized by huge outpatient clinics with excellent access to patient populations.
Our Clinical Research Centers in the United States specialize in the conduct and design of early stage, patient population studies, and are therapeutically focused in Human Abuse Liability (HAL), addiction, pain, psychiatry, neurology, pediatric and infectious disease services.
Our comprehensive areas of expertise range from a 16 DMII-patient panel in a multi-purpose protocol, early Proof of Concept, highly complex patients trails such as Renal/Hepatic impaired trials, ADME studies in oncology patients, to children with Tourette Syndrome.
At PRA, our established group of experts and facilities remain firm in our commitment to enrol patients into studies as early as possible.
ADME Studies in Oncology Patients
Central Nervous Systems